Emergent BioSolutions Inc. (EBS)
| Market Cap | 311.58M -42.6% |
| Revenue (ttm) | 649.10M -17.7% |
| Net Income | -260.70M |
| EPS | -5.04 |
| Shares Out | 51.42M |
| PE Ratio | n/a |
| Forward PE | 7.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,004,275 |
| Open | 5.79 |
| Previous Close | 5.85 |
| Day's Range | 5.78 - 6.07 |
| 52-Week Range | 4.36 - 14.06 |
| Beta | 2.37 |
| Analysts | Buy |
| Price Target | 10.00 (+65.02%) |
| Earnings Date | Nov 2, 2026 |
About EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for EBS stock is "Buy." The 12-month stock price target is $10.0, which is an increase of 65.02% from the latest price.
News
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS--Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order va...
Emergent BioSolutions trading resumes
09:37 EST Emergent BioSolutions (EBS) trading resumes
Emergent BioSolutions trading halted, volatility trading pause
09:32 EST Emergent BioSolutions (EBS) trading halted, volatility trading pause
Emergent BioSolutions Earnings Call Transcript: Q3 2026
Q3 revenue was $110 million, while YTD adjusted EBITDA reached $128 million and operating cash flow was $122 million. FY guidance calls for $600 million-$645 million in revenue; adjusted gross margin guidance rose to 45%-47%, amid delivery timing and naloxone market pressure.
Emergent BioSolutions Earnings release: Q3 2026
Emergent BioSolutions released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Emergent BioSolutions Slides: Q3 2026
Emergent BioSolutions has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Emergent BioSolutions Quarterly report: Q3 2026
Emergent BioSolutions has published its Q3 2026 quarterly earnings report on November 2, 2026.
Emergent BioSolutions reports Q3 adjusted EPS (36c), two estimates (39c)
Reports Q3 revenue $110M, consensus $123.2M. “Emergent’s third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medica...
Emergent BioSolutions cuts FY26 revenue view to $600M-$645M, consensus $657.12M
Previous view $645M-$675M. Cuts FY26 adjusted EBITDA view to $110M-$140M from $130M-$150M.
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2026. “Emergent's third-quarter results, which inc...
Emergent BioSolutions CFO Richard Lindahl to retire, Frank Vargo named interim
Emergent BioSolutions (EBS) announced that Richard Lindahl, EVP, CFO, will retire from the Company effective December 31. Frank Vargo, VP, treasurer, will assume the role of interim CFO effective Janu...
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS--Emergent BioSolutions Inc. (NYSE: EBS) today announced that Richard S. Lindahl, executive vice president, chief financial officer, will retire from the Com...
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, November 2, 2026, at 5:00 p.m. eastern time to discuss the financial results for the t...
Russian plague outbreak could boost these under-the-radar pharma stocks
Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irk...
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing res...
Emergent BioSolutions Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Leading in biodefense and opioid overdose solutions, the company reported strong financial results for 2026, reduced debt, and expanded its international footprint. Ongoing innovation and a robust pipeline address emerging threats, while operational restructuring enhances efficiency.
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875...
Emergent BioSolutions announces $24M modification from BARDA
Emergent BioSolutions (EBS) announced a contract modification valued at approximately $24M from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Pre...
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Re...
Emergent awarded standing offer by Government of Canada for Narcan Nasal Spray
Emergent BioSolutions (EBS) announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply Narcan Nasal Spray. The standing offer...
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitiv...
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE: EBS) is reaffirming its commitment to expanding awarene...
Emergent BioSolutions reinstated with an Underweight at JPMorgan
JPMorgan reinstated coverage of Emergent BioSolutions (EBS) with an Underweight rating and no price target The company is in a transition phase, with the recent setback from increasing competition in…
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $EBS--EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law.
EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions
Emergent BioSolutions cut its FY2026 adjusted EBITDA outlook to $130-$150 million from $155-$175 million amid continued NARCAN pricing and margin pressure, with NARCAN gross margin having fallen to 1...